Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OCTRU/CSM have recruited a new lead statistician to join the team.

Dr Iftekhar Khan has joined the CTU this week as Lead Statistician for our early phase and oncology trial portfolio. He joins us from King’s College, London, and prior to this he has worked in academia and industry over the last 15 years on clinical trials.

 

Dr Khan spoke to us about his interests and previous experience:

''I come with over 15 years experience in academia, industry and MHRA as a statistician. In previous jobs I have been head of Phase I at Eli LIlly, Merck and was responsible for Phase I trials at the UCL CRUK Cancer Trials Centre. I am also a senior statistical assessor within the licensing division of the MHRA. My interests lie in two areas at the extremes of the drug development spectrum: Phase I and Statistical Methods in Health Economics (I also happen to be a qualified health economist). I have written books on Design & Analysis of Clinical Trials for Economic Evaluation (Chapman & Hall; 2015); Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data (Chapman & Hall April 2019); and a forthcoming book on Sample Sizes For Clinical trial Trials Using Bayesian Methods (Chapman & Hall, due late 2019).

 I also like sailing, walking/trekking and playing cricket (when I can!).''

 

We look forward to expanding our portfolio of early phase trials with Dr Khan’s guidance.

Similar stories

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.

Building a humanoid bioreactor

A humanoid robot is being used at NDORMS in an attempt to grow tendon tissue for repairing shoulder injuries.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.